Valuation: ImmunityBio, Inc.

Market Cap 8.97B 7.82B 7.38B 6.7B 12.56B 860B 12.61B 88.43B 34.13B 437B 33.68B 32.93B 1,407B P/E 2026 *
-8.81x
P/E 2027 * -59.4x
Enterprise Value 8.97B 7.82B 7.38B 6.7B 12.56B 860B 12.61B 88.43B 34.13B 437B 33.68B 32.93B 1,407B EV / Sales 2026 *
39.7x
EV / Sales 2027 * 20.3x
Free-Float
37.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.83%
1 week+7.21%
Current month+6.67%
1 month+9.84%
3 months+15.22%
6 months-0.93%
Current year+328.28%
1 week 7.76
Extreme 7.76
8.8
1 month 7.46
Extreme 7.46
8.8
Current year 1.98
Extreme 1.98
12.43
1 year 1.95
Extreme 1.95
12.43
3 years 1.25
Extreme 1.25
12.43
5 years 1.21
Extreme 1.21
12.43
10 years 1.21
Extreme 1.21
40.83
Manager TitleAgeSince
Chief Executive Officer 57 2020-09-30
Chief Executive Officer 74 2015-02-28
Director of Finance/CFO 48 2021-02-28
Director TitleAgeSince
Director/Board Member 80 2021-01-31
Director/Board Member 71 2021-02-28
Chairman 74 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Exercice

Director

243,168 0.0232%
7/1/26 Exercice

Director

478,434 0.0457%
6/30/26 Exercice

Director

3,000 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+7.21%+197.54%+407.78% 8.97B
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-7.27%-17.73%+351.98% 27.07B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
-0.54%-0.56%+20.59%+224.93% 12.35B
Average -0.55%+2.47%+52.11%+248.57% 27.11B
Weighted average by Cap. -0.54%+1.66%+40.63%+172.87%

Financials

2026 *2027 *
Net sales 226M 197M 186M 169M 316M 21.66B 318M 2.23B 859M 11.01B 848M 829M 35.43B 441M 385M 363M 330M 618M 42.36B 621M 4.35B 1.68B 21.54B 1.66B 1.62B 69.3B
Net income -1B -876M -827M -751M -1.41B -96.35B -1.41B -9.9B -3.82B -48.98B -3.77B -3.69B -158B -150M -131M -124M -112M -211M -14.42B -211M -1.48B -572M -7.33B -565M -552M -23.59B
Net Debt - -
Logo ImmunityBio, Inc.
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy.
Employees
688
Date Price Change Volume
26-09-18 US$8.480 +0.24% 18,357,777
26-09-17 US$8.460 +6.95% 19,159,326
26-09-16 US$7.910 -2.83% 9,204,975
26-09-15 US$8.140 -2.75% 8,949,305
26-09-14 US$8.370 +5.82% 9,158,261
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.460USD
Average target price
12.75USD
Spread / Average Target
+50.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IBRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!